YC Biotech, the exclusive distributor of EG BioMed’s DNA methylation breast cancer detection technology, recently introduced this groundbreaking diagnostic tool to medical professionals at Xinmei Community Health Care Group in Tucheng. This advanced technology provides a more precise and innovative approach to early breast cancer detection, enhancing diagnostic accuracy and post-treatment monitoring.
Developed by EG BioMed, the DNA methylation breast cancer detection method leverages big data analysis to identify novel DNA methylation biomarkers. The technology integrates an early detection system, post-treatment monitoring capabilities, and automated analysis equipment, offering a comprehensive approach to cancer diagnostics. It has received prestigious recognitions, including the National Innovation Award and the National Science Council’s Future Technology Breakthrough Award. Additionally, it has undergone validation at leading medical institutions such as the Ministry of Health and Welfare’s Shuang Ho Hospital, National Taiwan University Hospital, Taipei Cancer Center, Wan Fang Hospital, and Taipei Medical University.
During the meeting, YC Biotech’s expert team provided an in-depth presentation to Xinmei Community Health Care Group’s physicians, detailing the scientific principles, clinical applications, and advantages of DNA methylation testing. The discussion highlighted how this innovative technology can improve diagnostic accuracy for patients while equipping healthcare providers with more comprehensive clinical insights.
The event laid the foundation for future collaboration, with multiple clinics within Xinmei Community Health Care Group expected to formalize agreements to implement the technology. This partnership will empower medical professionals with cutting-edge tools to enhance breast cancer detection, ultimately improving patient outcomes and advancing the quality of healthcare services.
